Press Release

PhRMA President and CEO Tauzin Will End Tenure in June

PhRMA April 30, 2013

Washington, D.C. (February 12, 2010) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzinannounced today that after more than five successful years, he will conclude his service as President and CEO at the end of June. To ensure a smooth transition, the search process for his successor will begin immediately. Mr. Tauzin also announced that he will continue to serve as PhRMA's leader until June 30, 2010 and will continue to serve in a consultancy role afterwards.

"We are grateful to Billy for his strong leadership and many accomplishments at PhRMA during these past five years, including his efforts to bring about health care reform,” said David Brennan, chief executive officer of AstraZeneca, and chairman of PhRMA. “Under his leadership, PhRMA has been a steadfast advocate of policies that support research and development and expand access to new medicines. Billy launched the Partnership for Prescription Assistance program to provide financial support to patients with the greatest need, and strengthened our voluntary codes on direct-to-consumer advertising, on clinical trials and on interactions with health care professionals. In addition, Billy brought a new openness to PhRMA's advocacy, ensuring that we partner with anyone willing to join us in our fight against disease. We wish him the best as he turns the page on another successful chapter in his career. With Billy's strong leadership and commitment to PhRMA's mission, the Board is confident that we can ensure a smooth transition to new leadership."

The search for Tauzin's successor will be led by the PhRMA Board's Nominations and Compensation Committee. In the meantime, PhRMA remains fully committed to achieving its primary mission of advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical research companies.

"In January 2005, after a full year successfully battling a killer cancer, I was given a second chance at life, and appropriately chose to commit my next five years to the life-saving work of the people whose miracle medicines had just saved my own," said Tauzin. "For the past five years, I have given my all to that effort at PhRMA, and believe we have made a significant difference together.”

Tauzin added, "PhRMA’s work is not limited to Washington D.C. It is global, representing research companies from Japan, throughout Europe and across America in addition to supporting patients worldwide. PhRMA works for those patients and research companies in capitals across the globe, and in capitals in our 50 states and territories. PhRMA’s goals are unchanged and unchangeable: to help our companies innovate and develop the medicines of the future to successfully battle every disease known to mankind.

"I have been honored to be a part of that work. As the first ever cancer patient to lead PhRMA as its CEO, I now believe it is time I move on and hand the mantle of leadership of this great organization to others as passionate as myself, and to explore the many other interests I would like to pursue in this special second-chance life that I have been given. My health is excellent and I look forward to exciting new challenges ahead.

"My commitment in January 2005 was for five and a half years of service, and I will have fulfilled that commitment this summer. By then, I hope and expect that a great successor will have been chosen, and I intend to work with PhRMA’s new CEO to ensure a smooth and successful transition.

"While I will soon leave my current assignment on behalf of the biopharmaceutical community and their patients, I fully expect to continue to assist their mission in new and different ways. I will always be grateful to have worked for and with the extraordinary team here at PhRMA who work every day to support the life-giving work of PhRMA’s member companies and their amazing scientists."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For more information on public health emergencies, visit:

For information on the danger of imported drugs, visit: